Ausgabe 2/2004
Inhalt (15 Artikel)
Original Papers
The risk-adjusted vision beyond casemix (DRG) funding in Australia
Kathryn M. Antioch, Michael K. Walsh
Erratum
The risk-adjusted vision beyond casemix (DRG) funding in Australia
Kathryn M. Antioch, Michael K. Walsh
Original papers
Genetic screening, health care and the insurance industry
Diego F. Ossa, Adrian Towse
Original Papers
Price-cost margin in the pharmaceutical industry
Ismo Linnosmaa, Raine Hermans, Taru Hallinen
Original Papers
Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease
Thomas Hoffmann, Helmut Brunner
Original Papers
Potential cost-effectiveness of a family-based program in mild Alzheimer’s disease patients
Janne Martikainen, Hannu Valtonen, Tuula Pirttilä
Original Papers
Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine
Francis Fagnani, Camille Le Fur, Isabelle Durand, Michel Gibergy
An empirical analysis of the demand for physician services across the European Union
Sergi Jiménez-Martín, José M. Labeaga, Maite Martínez-Granado
Invited Papers
Dynamic competition in pharmaceuticals
Laura Magazzini, Fabio Pammolli, Massimo Riccaboni
Scientific Information
The European Network of Health Economic Evaluation Databases (EURO NHEED) Project
John Nixon, Philippe Ulmann, Julie Glanville, Stéphanie Boulenger, Michael Drummond, Gérard de Pouvourville
Commentary
“Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK”
Nick Bansback, Sue Ward, Jon Karnon
Pricing and Reimbursement Systems
Pricing and reimbursement of drugs in Ireland
Michael Barry, Lesley Tilson, Máirín Ryan